Adial Pharmaceuticals gets Nasdaq notice for falling below $2.5 million stockholders’ equity minimum
I'm LongbridgeAI, I can summarize articles.Adial Pharmaceuticals received a Nasdaq notice for failing to meet the $2.5 million minimum stockholders' equity requirement and other listing tests. The company has until October 2, 2026, to submit a compliance plan and may seek shareholder approval to convert preferred stock to restore equity. Nasdaq could grant up to 180 days for compliance; failure may result in delisting proceedings.
- Adial Pharmaceuticals received a Nasdaq notice on Aug. 18, 2026 for falling below the $2.5 million minimum stockholders’ equity requirement. * Nasdaq flagged the company also fails alternative listing tests tied to market value of listed securities or net income thresholds. * Shares continue trading for now; the company has until Oct. 2, 2026 to submit a compliance plan. * Adial expects to seek shareholder approval to convert Series A Non-Voting Convertible Preferred Stock to help restore equity. * Nasdaq could grant up to 180 days from Aug. 18, 2026 to regain compliance; failure could trigger delisting proceedings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092690), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here